What is toxic top-line revenue in a dental practice?

Toxic Top-Line is revenue that is real — produced, billed, and collected — but not defensible under institutional scrutiny. It sits in the P&L like every other dollar, inflates EBITDA today, and gets stripped in diligence when a buyer's clinical analytics flag the code-level pattern behind it. The distinction that matters in a sale is not real versus fake revenue; it is defensible versus indefensible revenue.

What is a normal core buildup to crown ratio?

Roughly 40%. Cotiviti — the payment-integrity analytics firm whose tooling sits inside the major insurers — models about 40% of crowns as expected to require a core buildup, keyed to the documentation threshold payers enforce: missing tooth structure exceeding 50%. A practice billing buildups on 76.9% of crowns, as in the worked case here, is at nearly double the modeled rate — which gets flagged on a diligence team's first pass, not investigated on their third.

How do buyers find coding inflation during due diligence?

They run the same class of clinical analytics insurers use for payment integrity, pointed at the seller's raw PMS export. Code-level production is benchmarked by ratio — buildups to crowns, scaling to prophy, radiograph frequency — and outliers are treated as non-continuing revenue: production the buyer's own compliance standards would not allow them to keep generating. The buyer refuses to pay a multiple on it, then prices the look-back risk on top through escrows and indemnities.

Is a high buildup ratio a clinical problem or a documentation problem?

At most practices, documentation. The ADA's clinical guidance on when a buildup is appropriate is broader than the payer's evidentiary threshold of greater-than-50% structure loss. A dentist can be clinically right while the chart fails the payer's bar — no recorded structure-loss percentage, no pre-op image, no narrative. In an audit or diligence review, the chart is the only witness that gets called. The fix is a charting protocol enforced for 90 days, not clinical retraining.

How much enterprise value can one code family put at risk?

In the worked case: a general department produced 2,153 crowns with 1,656 carrying buildup codes — 76.9% against a ~40% benchmark. Annualized buildup production was $227,000, of which roughly $108,000 sat above the benchmark. At a 6× multiple, that is approximately $650,000 of enterprise value exposure from one code family in one department — before any retroactive payer clawback risk is priced on top.

Financial Analytics

Toxic Top-Line: The Revenue That Counts Until Someone Checks

James DeLuca July 13, 2026 7 min read

A $12 million multi-specialty practice. Clean books. A CPA who signs the financials without a second look. And $227,000 a year of production that a buyer’s analyst will refuse to price.

Not fraud. Not billing errors. Every dollar was produced, billed, and collected. The revenue is real.

It just isn’t defensible. And in institutional diligence, real and defensible are different things.

The division that exposes it quickly

Here’s the whole discovery. It’s one simple calculation.

When a tooth is too broken down to hold a crown, the dentist rebuilds the missing structure first using a core buildup, billed under its own code (D2950 and its siblings) alongside the crown. Some crowns need one. Most don’t by payer standards. So the ratio of buildups to crowns is a signal: how often does this practice bill the add-on procedure relative to the base one?

In the practice above, the general department produced 2,153 crowns year-to-date. 1,656 of them carried a buildup code.

That’s 76.9 percent.

The benchmark is roughly 40. Cotiviti (the payment-integrity analytics firm whose tooling sits inside the major insurers) models about 40 percent of crowns as expected to require a buildup, keyed to the documentation threshold payers actually enforce: missing tooth structure exceeding 50 percent. That threshold is deliberately more conservative than the ADA clinical standard. Hold that thought. It’s the trap.

At 76.9 percent, this practice bills buildups at nearly double the modeled rate. Annualized buildup production: $227,000. Production above the benchmark: $108,000 a year. At a six-multiple, roughly $650,000 of enterprise value exposure.

One code family. One department. One calculation.

Why this is “toxic” revenue

This revenue does three things at once, and each is worse than the last.

It inflates EBITDA today. The buildups were billed and collected. They sit in the P&L like every other dollar, and your CPA, working from the financials, accurately counts them. Nothing on an income statement distinguishes a defensible dollar from an indefensible one.

It dies in diligence. Institutional buyers now run clinical analytics against code-level production data as standard practice — the same class of tooling insurers use for payment integrity, pointed at your PMS export. A 76.9 percent ratio doesn’t get investigated. It gets flagged on the first pass, and the production above the benchmark gets treated as non-continuing: the buyer refuses to pay a multiple on revenue their own compliance standards wouldn’t allow them to keep producing.

And it points backward. An outlier ratio isn’t only a valuation problem — it’s an audit trigger. Payers run the same analytics you’re being scored by in diligence, and a flagged ratio invites retroactive claim review and clawback of dollars already paid. A buyer prices that exposure with discounts, escrows, and indemnities. Whichever instrument they choose, it comes out of the seller.

Revenue that counts until someone checks. That’s Toxic Top-Line.

The part that should change how you read this

Here’s what almost nobody tells the seller: at most practices, this is a documentation problem, not a clinical one.

Remember the two standards. The ADA’s clinical guidance on when a buildup is appropriate is broader than the payer’s evidentiary threshold. A dentist can be entirely right by their clinical training. The tooth genuinely needed the buildup. And the claim can still fail the payer’s bar, because the chart never recorded the percentage of missing structure, never captured the pre-op image, never wrote the two-sentence narrative that proves the threshold was met.

The dentistry was defensible. The chart isn’t. And in an audit or a diligence review, the chart is the only witness that gets called.

Which means the fix is charting protocol, not clinical retraining. Run the ratio provider by provider. In a fifteen-provider group, the outliers are rarely everyone. Institute a documentation standard: charted evidence of greater-than-50-percent structure loss on every buildup submission, image attached, narrative written. Enforce it for 90 days and re-run the division. The target for this practice was a ratio below 45 percent, but the real target is subtler than a number. Not a lower ratio. A provable one.

A documentation standard change, not a clinical judgment change. Ninety days of habit against six hundred fifty thousand dollars of exposure.

Sellers lose six figures over paperwork.

The third face of Phantom EBITDA

If you’ve read my work, you know the first two faces of Phantom EBITDA. The accounting face: add-backs and normalizations that don’t survive a QoE. The operational face: the aged AR that needs a reserve, the collection anomalies with no clinical explanation.

This is the third face, and the least visible: the clinical face. Production that fails at the code level. It’s the same blind spot that makes EBITDA Laundering possible — profit from non-compliant coding passing through financial underwriting undetected — seen from the seller’s side of the table.

It’s the least visible because no one in the seller’s corner can see it. Your CPA works from the P&L; code-level production never crosses their desk. Your broker markets the practice; nobody at the brokerage is running D2950 ratios. Your practice management consultant is watching production go up, which is the whole problem — this failure mode looks like success from every seat the seller can buy. And worst of all, the lawyer you hired to represent you never received the proof they needed to defend you.

The buyer’s side changed. Clinical analytics moved from insurer back-offices into standard diligence kit at the institutional tier. The buyer’s analyst now sees a layer of your practice that your entire advisory team has never looked at.

And buildups are only the cleanest example with both a public benchmark and one-division math. The structure repeats in any code family where production outruns what documentation can defend: scaling ratios, radiograph frequency, adjunctive services. Same pattern, same discovery, same discount.

The timing

All of this lives in exactly one place: your practice management system. Which means it is findable years before an LOI exists by running the same division the buyer will, well before they do.

Before the LOI, this is a 90-day documentation fix. After the LOI, the ratio is what it is. You’re not repairing the exposure anymore. You’re negotiating how much of it you eat. That is why the exit timeline starts years out, not months.

A buyer’s analyst will pull these two numbers from your PMS and divide them. Then they’ll do it for every code family you bill.

Run the math first.

Educational, not clinical or billing-compliance advice. Documentation thresholds and payer standards vary by carrier and state; your compliance counsel and clinical team run your specifics. To see the rest of what a buyer’s first pass will flag, start with the EBITDA Leakage Diagnostic or the free Defense Gap field guide.

About the author — James DeLuca is the founder of Precision Dental Analytics and a leading expert in Clinical Data Forensics and M&A Defense. Acting as the elite “Red Team” for multi-location founders and sell-side brokers, he mathematically hardens clinical architecture before founders face institutional due diligence. He is the author of Phantom EBITDA, Spartan Leadership, The Dental Data Playbook, and Hidden Levers. Meet the team →

Frequently Asked

Questions

What is toxic top-line revenue in a dental practice?: Toxic Top-Line is revenue that is real — produced, billed, and collected — but not defensible under institutional scrutiny. It sits in the P&L like every other dollar, inflates EBITDA today, and gets stripped in diligence when a buyer's clinical analytics flag the code-level pattern behind it. The distinction that matters in a sale is not real versus fake revenue; it is defensible versus indefensible revenue.
What is a normal core buildup to crown ratio?: Roughly 40%. Cotiviti — the payment-integrity analytics firm whose tooling sits inside the major insurers — models about 40% of crowns as expected to require a core buildup, keyed to the documentation threshold payers enforce: missing tooth structure exceeding 50%. A practice billing buildups on 76.9% of crowns, as in the worked case here, is at nearly double the modeled rate — which gets flagged on a diligence team's first pass, not investigated on their third.
How do buyers find coding inflation during due diligence?: They run the same class of clinical analytics insurers use for payment integrity, pointed at the seller's raw PMS export. Code-level production is benchmarked by ratio — buildups to crowns, scaling to prophy, radiograph frequency — and outliers are treated as non-continuing revenue: production the buyer's own compliance standards would not allow them to keep generating. The buyer refuses to pay a multiple on it, then prices the look-back risk on top through escrows and indemnities.
Is a high buildup ratio a clinical problem or a documentation problem?: At most practices, documentation. The ADA's clinical guidance on when a buildup is appropriate is broader than the payer's evidentiary threshold of greater-than-50% structure loss. A dentist can be clinically right while the chart fails the payer's bar — no recorded structure-loss percentage, no pre-op image, no narrative. In an audit or diligence review, the chart is the only witness that gets called. The fix is a charting protocol enforced for 90 days, not clinical retraining.
How much enterprise value can one code family put at risk?: In the worked case: a general department produced 2,153 crowns with 1,656 carrying buildup codes — 76.9% against a ~40% benchmark. Annualized buildup production was $227,000, of which roughly $108,000 sat above the benchmark. At a 6× multiple, that is approximately $650,000 of enterprise value exposure from one code family in one department — before any retroactive payer clawback risk is priced on top.